Status:
RECRUITING
Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis
Lead Sponsor:
University of Pennsylvania
Collaborating Sponsors:
GlaxoSmithKline
AstraZeneca
Conditions:
Eosinophilic Granulomatosis With Polyangiitis
Churg-Strauss Syndrome
Eligibility:
All Genders
Brief Summary
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflamma...
Detailed Description
EGPA, also known as allergic granulomatosis angiitis, is a systemic vasculitis. EGPA is marked by three distinct symptoms: asthma; eosinophilia, evidenced by an excessive number of eosinophils in the ...
Eligibility Criteria
Inclusion
- Patients with a diagnosis of eosinophilic granulomatosis with polyangiitis are eligible for the study.
- Parent or guardian willing to provide informed consent, if applicable
Exclusion
- \- Inability to give informed consent and to sign the consent form
Key Trial Info
Start Date :
April 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 1 2028
Estimated Enrollment :
700 Patients enrolled
Trial Details
Trial ID
NCT00315380
Start Date
April 1 2006
End Date
December 1 2028
Last Update
May 21 2025
Active Locations (10)
Enter a location and click search to find clinical trials sorted by distance.
1
University of California San Diego
San Diego, California, United States, 92122
2
National Jewish Health
Denver, Colorado, United States, 80206
3
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02215
4
Mayo Clinic
Rochester, Minnesota, United States, 55905